Skip to content

Nurix Therapeutics, Inc. NRIX Area of office space leased

Area of office space leased at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$98.81K
Q2 Holdings logo
Q2 HoldingsQTWO
20.0%
KLR
Kailera Therapeutics KLRA
39.5K
Arrowhead Research logo
Arrowhead ResearchARWR
144K
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
2-66.7%
FRM
Fermi Inc. Common StockFRMI
$15M

Segments

By geography

See full
Brisbane, California35.9K

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept nrix:AreaOfOfficeSpaceLeased.

The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s area of office space leased.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s area of office space leased?
Nurix Therapeutics, Inc. (NRIX) reported area of office space leased of 57.9K in Q3 2025.
What does area of office space leased mean?
This measures the total square footage of office and laboratory space currently under lease agreements. It serves as a proxy for the company's physical operational footprint and infrastructure scale. Changes in this metric often correlate with headcount growth or expansion of research and development capabilities.